Barclays Maintains Overweight on Insmed, Lowers Price Target to $207

Benzinga Newsdesk www.benzinga.com Negative 92.8%

Neg 92.8% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.